Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 08 - 15

Progen's Recombinant Human Serum Albumin Injection Achieves Key Progress in Phase III Study

Recently, the pivotal Phase III clinical study of Progen's fully in-house developed Recombinant Human Serum Albumin (rHSA) Injection for the indication of cirrhosis-induced ascites successfully met the primary efficacy endpoint and key secondary efficacy endpoints required by the National Medical Products Administration (NMPA). The New Drug Application (NDA) for market approval has been fully initiated.The Phase III clinical study of Progen's Recombinant Human Serum Albumin Injection for the cirrhosis-induced ascites indication adopted a multi-center, randomized, double-blind, active-c...

浏览次数：1

查看详情>>

发布时间: 2025 - 08 - 14

Efung Capital CEO Zhu Pui Honored on Fortune China's 2025 "40 Under 40" Most Promising Business Elit

Recently, Fortune (Chinese edition) released its "China's 40 Under 40 Business Elite" list. Zhu Pui, CEO of Efung Capital, was honored on Fortune China's 2025 "40 Under 40" Most Promising Business Elite list, showcasing the forward-looking vision and business acumen of the younger generation of entrepreneurs.This year's list continues the dual-track selection mechanism from previous years, featuring both the "China's 40 Under 40 Business Elite" list and the "China's 40 Under 40 Most Promising Business Elite" list. The former recognize...

浏览次数：2

查看详情>>

发布时间: 2025 - 08 - 07

Aofumin® Selected into the Ministry of Industry and Information Technology's List of Biom Manufactur

Recently, China's Ministry of Industry and Information Technology (MIIT) announced the 2024 List of Biom Manufacturing Flagship Products (First Batch). A total of 36 flagship products were selected, covering multiple sub-sectors such as biomaterials, biochemicals, and biomedicine, fully demonstrating China's cutting-edge technological achievements in the field of biom manufacturing and setting benchmarks for future industrial development. Oryzogen's newly approved product, Aofumin®—Recombinant Human Albumin Injection (produced in rice)—was successfully selected, showcasing the...

浏览次数：1

查看详情>>

发布时间: 2025 - 08 - 04

Stepping Forward with Distinction! Efung Capital and Its Portfolio Companies Honored with Multiple I

Recently, Efung Capital and several of its invested biopharmaceutical companies have won multiple awards in various authoritative selections, thanks to their exceptional innovation capabilities and industry contributions. Notably, in the TMTPost 2025 H1 Pioneer List, Efung Capital was honored among the Top 20 in the Healthcare Sector. In the Hao Yue Capital Excellence Awards, Core Medical, Norling Bio, and Yingmingda were recognized as Best Innovative Medical Device Companies of the Year, while Coning Bio and Westlake Biosciences were honored as Best Innovative Pharmaceutical Co...

浏览次数：1

查看详情>>